<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981862</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01085-46</org_study_id>
    <nct_id>NCT02981862</nct_id>
  </id_info>
  <brief_title>CaptHPV : Validation of the Method &quot;CaptHPV&quot; for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas</brief_title>
  <acronym>CaptHPV</acronym>
  <official_title>Monocentric Study of Validation of the Method &quot;CaptHPV&quot; for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas From a Biological Specimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current project is based on the assumption that a diagnosis of human papillomavirus
      associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical
      Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer, Oral Cavity Cancer or Penis Cancer at
      any stage of the disease and including surgical treatment for the small tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2016</start_date>
  <completion_date type="Actual">June 12, 2018</completion_date>
  <primary_completion_date type="Actual">June 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessement of CaptHPV method</measure>
    <time_frame>1 day</time_frame>
    <description>The diagnostic value of the serum marker provided by the method CaptHPV will be assessed in sensitivity and specificity to results of histological and virological analyzes of a sample tumor.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Oral Cavity Cancer</condition>
  <condition>Penis Cancer</condition>
  <arm_group>
    <arm_group_label>CaptHPV method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CaptHPV method</intervention_name>
    <description>20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.
In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology
The results of both analyzes will be compared blindly.</description>
    <arm_group_label>CaptHPV method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patient with cervical cancer, vulvar cancer, anal cancer, oropharynx cancer, oral
             cavity cancer or penis cancer

          -  Patient naive of any treatment for this pathology

          -  Patient capable and willing to follow all procedures of the study in accordance with
             the study

          -  Ability to provide an informed written consent form

          -  Affiliation to a social security system

        Exclusion Criteria:

          -  Patients who have already undergone surgical treatment leading to complete removal of
             the lesions or who have started treatment with radiotherapy and / or chemotherapy

          -  Patient whose health status contraindicates a blood sample of 20 ml,

          -  Absence of informed written consent form

          -  Pregnant or breast feeding females

          -  Patients deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SASTRE-GARAU Xavier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV infection</keyword>
  <keyword>Blood sample</keyword>
  <keyword>Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

